These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1408 related articles for article (PubMed ID: 25259745)

  • 1. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E; Bots ML; van Zuilen AD; Wetzels JF; Blankestijn PJ;
    Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.
    Thomas G; Xie D; Chen HY; Anderson AH; Appel LJ; Bodana S; Brecklin CS; Drawz P; Flack JM; Miller ER; Steigerwalt SP; Townsend RR; Weir MR; Wright JT; Rahman M;
    Hypertension; 2016 Feb; 67(2):387-96. PubMed ID: 26711738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR; Booth JN; Shimbo D; Lackland DT; Oparil S; Howard G; Safford MM; Muntner P; Calhoun DA
    J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Kronish IM; Lynch AI; Oparil S; Whittle J; Davis BR; Simpson LM; Krousel-Wood M; Cushman WC; Chang TI; Muntner P
    Hypertension; 2016 Jul; 68(1):39-45. PubMed ID: 27217410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
    Bakris G; Lin PP; Xu C; Chen C; Ashton V; Singhal M
    J Clin Hypertens (Greenwich); 2024 May; 26(5):500-513. PubMed ID: 38523465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
    Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
    J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
    Bangalore S; Fayyad R; Laskey R; Demicco DA; Deedwania P; Kostis JB; Messerli FH;
    Am J Med; 2014 Jan; 127(1):71-81.e1. PubMed ID: 24210549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
    Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study.
    Langford AT; Akinyelure OP; Moore TL; Howard G; Min YI; Hillegass WB; Bress AP; Tajeu GS; Butler M; Jaeger BC; Yano Y; Shimbo D; Ogedegbe G; Calhoun D; Booth JN; Muntner P
    Hypertension; 2020 Nov; 76(5):1600-1607. PubMed ID: 32924633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.
    Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M
    J Clin Hypertens (Greenwich); 2023 Aug; 25(8):737-747. PubMed ID: 37461262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.